InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder
September 10, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (“MDD”) in the first half of 2027, with dosing expected to be completed by year-end. […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate in IPAC-RS 2026 Nasal Innovation Forum
September 9, 2026
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, announced that company representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, taking place Sept. 16-17, 2026, in Jersey City, New Jersey. CEO Eric Weisblum said the forum provides an […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Canadian Patent Allowance for Lead Asset SPC-15
August 19, 2026
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform subsidiary, announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Completes Enrollment in Phase 3 Depression Study
July 21, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced it has completed enrollment in its pivotal Phase 3 APPROACH trial evaluating HLP003 as an adjunctive treatment for adults with moderate to severe major depressive disorder who have not achieved an adequate response to antidepressant therapy. The study enrolled 223 participants […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Subsidiary QwikAgents Joins AMD AI Developer Program
July 14, 2026
Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ AMD AI Developer Program, providing access to AMD Developer Cloud credits, AI development tools, training resources and a global developer community. The company said the program is expected to accelerate development, testing, optimization and deployment of its […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances SPC-15 Intranasal PTSD Program With Device Robustness Study
June 30, 2026
Silo Pharma (NASDAQ: SILO), announced that drug-device development partner Resyca will conduct a robustness study of the microchip-based Soft-Mist Nasal Spray system used to deliver SPC-15, the company’s lead intranasal prophylactic treatment candidate for post-traumatic stress disorder. The study will evaluate device performance consistency and the stability of SPC-15 and placebo formulations over a 30-day […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial
June 10, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished […]
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
June 10, 2026
VANCOUVER, British Columbia, June 10, 2026 (GLOBE NEWSWIRE) — via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program
June 8, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company expects development of finished ibogaine drug products to begin this summer at its GMP-certified manufacturing facility in […]
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
June 8, 2026
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder and traumatic brain injury VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) — via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
June 2, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product […]
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
June 2, 2026
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi“), a commercial-stage pharmaceutical […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
May 29, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment […]
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
May 29, 2026
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) — via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi“), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration (“TGA”) following its targeted consultation on the Authorized Prescriber (“AP”) scheme for psilocybin and MDMA. Under the […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
May 27, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company’s position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales. The […]
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
May 21, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market, offering 2.4 million common shares at US$6.25 per share for expected gross proceeds […]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast
May 15, 2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, used a recent appearance on the TechMediaWire Podcast to outline how the company plans to commercialize its technology, starting with […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Launches Ibogaine-Based TBI Therapeutics Initiative
May 7, 2026
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury and related neuropsychiatric conditions, including the filing of a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD and associated […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Federal Momentum Advancing Psychedelic Therapeutics Development
April 29, 2026
Silo Pharma (NASDAQ: SILO) commented on a series of coordinated U.S. federal actions accelerating the development of psychedelic-based therapies for mental health and substance use disorders, citing new funding initiatives, clinical progress and regulatory advancements. The company pointed to programs from agencies including ARPA-H and the FDA, such as IND clearance for a noribogaine candidate and the issuance of priority […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Into AI With Qwikagents Asset Acquisition
April 23, 2026
Silo Pharma (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The company said the move positions it to capitalize on a rapidly growing […]
InvestorNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift
April 21, 2026
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) announced the launch of its Ibogaine Initiative to expand its Health Canada-licensed GMP manufacturing platform to include ibogaine production and supply, aligning with emerging U.S. regulatory momentum to accelerate psychedelic research and patient access. The move follows a […]
From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research
April 8, 2026
Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large and complex biomedical datasets, which are often incredibly difficult and time-consuming to go through manually. Trying to analyze the datasets manually just isn’t feasible in most cases, not only due to the amount of time and […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent
April 7, 2026
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the European Patent Office has issued a Rule 71(3) communication indicating its intent to grant a patent covering methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 (5-HT4) […]
Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
March 26, 2026
Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Authorizes $1 Million Share Repurchase Program
February 24, 2026
Silo Pharma (NASDAQ: SILO) announced that its board of directors authorized a share repurchase program to acquire up to $1 million of the company’s common stock. Purchases may occur on the open market, through privately negotiated transactions or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The company reported 13,318,273 shares of common […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10
February 18, 2026
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal therapeutic targeting post-traumatic stress disorder. The application, titled “Compositions and […]
Xeriant Inc. (XERI) Builds Innovation Ecosystem Focused on Advanced Technologies, Commercialization
February 6, 2026
As investor interest in advanced technology platforms grows alongside breakthroughs in research, materials science and data-driven innovation, Xeriant (OTCQB: XERI) is shaping a strategy that extends well beyond any single product or material solution. Rather than positioning itself as a one-technology company, Xeriant is increasingly defining its identity around building an integrated innovation ecosystem focused […]
The Quiet Shift in Capital Markets: Why Liquidity Is Being Engineered, Not Waited For, and How DealFlow Discovery Fits In
January 26, 2026
One of the most under-discussed changes in capital markets heading into 2026 isn’t valuation, rates, or even IPO volume, it’s how liquidity itself is being created. For much of the last decade, liquidity followed a familiar path: private funding rounds, a public listing, then secondary trading. That sequence has fractured. Today, liquidity is increasingly designed, […]
Why 2026 Is a Pivotal Year for Private, Pre-IPO, and Microcap Investing, and What That Means for DealFlow Discovery
January 23, 2026
As we head into January 2026, the capital markets landscape is in a period of subtle but consequential transition, one that has real implications for the direction of private company financings, pre-public valuations, and the small-cap ecosystem that DealFlow Discovery Conference now reflects. For years, microcap investing sat at the intersection of retail enthusiasm and […]
Xeriant Inc. (XERI) Expands Leadership Role for Prominent Military Veteran to Drive Innovation
January 21, 2026
As emerging technologies increasingly intersect with national security, infrastructure resilience and advanced materials development, companies are placing greater emphasis on leadership that understands both innovation and real-world operational demands. Experience in defense, aerospace and strategic risk assessment has become especially valuable as firms pursue cutting-edge research with broad civilian and government applications. With this in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Transfer of U.S. Listing to Nasdaq and Ticker Change to HELP
December 18, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The Company expects its common shares […]
Datavault AI Inc. (NASDAQ: DVLT) CEO Featured in Interview Noting AI Growth, Challenges
December 4, 2025
Artificial intelligence (“AI”) is accelerating across nearly every sector, reshaping how companies innovate, compete, and protect their digital assets. Datavault AI Inc. (NASDAQ: DVLT), a data-centric enterprise AI company, is working to ensure organizations of all sizes can deploy, secure and scale AI systems built on trustworthy data. The company’s platform helps transform fragmented, unstructured information […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
November 13, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN) reported second-quarter 2025 results and recent business highlights, noting strong institutional demand for its completed financing, which Interim CEO Eric So said reinforces confidence in the company’s science, differentiated therapeutic candidates and ability […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Jefferies Global Healthcare Conference in London
November 12, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company developing proprietary drug discovery platforms and delivery systems to transform mental healthcare, today announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sets Nov. 13 Call to Review Q2 Results and Business Update
November 6, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), will host a conference call and webcast at 8 a.m. ET Thursday, Nov. 13, 2025, to provide a business update and report financial results for its second quarter ended Sept. 30, 2025. To […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Guggenheim 2nd Annual Healthcare Innovation Conference
November 5, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery and delivery technologies, announced that Chief Business Officer George Tziras will participate in a fireside chat at […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Speak at 2025 Milken Institute Future of Health Summit
November 3, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering transformative mental health treatments, today announced that its Chief Medical Officer, Amir Inamdar, will participate in a panel discussion at the 2025 Milken Institute Future of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Closes US$175 Million Registered Direct Offering Led by Top Healthcare Investors
October 31, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering next-generation mental health therapeutics, announced the closing of its previously disclosed registered direct offering for gross proceeds of approximately US$175 million. The financing included 22,277,750 common […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces US$175M Registered Direct Offering With Warrants Priced at US$6.51
October 28, 2025
This article has been disseminated on behalf of Cybin and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced a registered direct offering of 22,277,750 common shares and, in lieu of shares for certain investors, pre-funded common share purchase warrants at US$6.51 per share or pre-funded warrant for aggregate gross proceeds of US$175,009,911.45; […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Highlights Clinical and Regulatory Milestones, Prepares for Upcoming Catalysts
September 24, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company, outlined key advancements across its proprietary drug discovery platforms and upcoming milestones. The Company emphasized its intellectual property portfolio extending through 2041 and its scalable manufacturing partnership with Thermo Fisher Scientific for the CYB003 program. Key near- and mid-term catalysts include topline data […]